AIT Therapeutics Inc., a clinical-stage biopharma company developing inhaled Nitric Oxide (NO) for the treatment of serious lung infections and pulmonary hypertension, has appointed two new executive team members. Mark Rimkus was appointed vice president of Clinical Affairs and will assist in clinical trial management, quality systems development, device design and device testing. Dr. Abdi Ghaffari was named vice president of Research and will provide preclinical and scientific expertise to deve...